COMMUNIQUÉS West-GlobeNewswire

IBA Notice of Full Year 2025 Results and Conference Call
13/03/2026
FY25 results webcast to take place on Friday, 27 March 2026 at 3pm CET Louvain-la-Neuve, Belgium, 13 March 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, [...]
Now Available: Fresh Bloom THCA Flower Subscription Box by The Hemp Doctor
13/03/2026
MOORESVILLE, N.C., March 13, 2026 (GLOBE NEWSWIRE) -- The Hemp Doctor introduces the Fresh Bloom THCA Flower Subscription Box , a monthly drop of hand-selected flower and pre-rolls delivered to your door, including [...]
Novonesis issues EUR 1.7 billion senior unsecured notes
13/03/2026
On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly [...]
IBA : Publication des résultats annuels 2025 et conférence web
13/03/2026
La conférence sur les résultats de l’exercice 2025 aura lieu le vendredi 27 mars 2026 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 13 mars 2026 - IBA (Ion Beam Applications S.A le leader mondial des [...]
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
13/03/2026
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
13/03/2026
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes [...]
The Ensign Group to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 19, 2026
12/03/2026
SAN JUAN CAPISTRANO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]
Voting Rights and Shares Capital of the Company
12/03/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 12, 2026 (GLOBE NEWSWIRE [...]
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
12/03/2026
Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026 Fewer disease [...]
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
12/03/2026
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director [...]
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
12/03/2026
MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on [...]
Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026
12/03/2026
NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
12/03/2026
Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) [...]
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
12/03/2026
The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq [...]
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
12/03/2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
TerrAscend Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing operations of $ [...]
VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results
12/03/2026
TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has updated the date for the release of its financial results for the fourth [...]
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected [...]
Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
12/03/2026
Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE [...]

Pages